Agilent buys cell metabolism company for $235m

Skip to Navigation


  • Published: Sep 11, 2015
  • Author: Jon Evans
  • Source: Agilent Technologies
  • Suppliers: Agilent Technologies
  • Channels: HPLC / Detectors / Gas Chromatography / Laboratory Informatics / Sample Preparation / Electrophoresis / Proteomics & Genomics / Ion Chromatography / Infrared Spectroscopy / NMR Knowledge Base / Raman / MRI Spectroscopy / Base Peak / Atomic / Chemometrics & Informatics / Proteomics / X-ray Spectrometry / UV/Vis Spectroscopy

Agilent Technologies has announced its acquisition of Seahorse Bioscience, a US developer of instruments and assay kits for measuring cell metabolism and bioenergetics, for $235 million.

Exploration of cell metabolism is rapidly accelerating as the links between mitochondrial function and disease are increasingly revealed. Seahorse Bioscience’s leading technology allows researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data.

Scientists can use Seahorse Bioscience’s proprietary XF Technology to research the role of cell metabolism in a range of diseases and biological processes, including neurodegenerative diseases, cancer, cardiovascular disease, aging, obesity, diabetes and metabolic disorders.

‘Seahorse Bioscience’s unique technology is the perfect complement to Agilent’s market-leading separations and mass spectrometry solutions, in particular for metabolomics research and disease research in pharma,’ said Patrick Kaltenbach, president of Agilent’s Life Sciences and Applied Markets Group. ‘The combination of these two platforms gives scientists a more comprehensive and faster path to researching the most challenging diseases affecting mankind. Seahorse’s team and technology are an ideal fit for Agilent and for our customers, and we look forward to bringing them on board.’

‘We are proud to have enabled the exploration of bioenergetics in living cells by nearly 10,000 scientists worldwide, and to have created a new category of cell-based assay tools,’ said Jay Teich, chief executive officer of Seahorse Bioscience. ‘Joining Agilent, a premier, customer-focused supplier of technology to a much broader market, will give many more researchers access to Seahorse tools. And when these two technology-rich companies combine, we expect to offer a series of new products and applications that will benefit our customers.’

Privately-held Seahorse Bioscience, founded in 2001, has its headquarters in Billerica, Massachusetts, with manufacturing operations in Chicopee, Massachusetts. Regional offices are in Copenhagen, Denmark, and Shanghai, China. Seahorse Bioscience employs just under 200 people, most of whom are expected to join Agilent, and its revenue this financial year is estimated to be $49 million.

The acquisition is expected to be completed by 1 November 2015, subject to local laws and regulations and customary closing conditions.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2019 John Wiley & Sons, Inc. All Rights Reserved